Dr Rosanne Dunn
Dr Rosanne Dunn is Executive Director and Chief Scientific Officer at HaemaLogiX. As a co-founder of the company she has been a director since its incorporation. Rosanne has more than 20 years of experience in the fields of immunology, haematology, translational medicine and drug development. She was involved in the discovery of the company’s lead therapeutic antibody KappaMab™ and in taking the antibody from the laboratory through to preclinical and clinical development.
Rosanne was also involved in the design of the KMCAR™-T construct and heads the HaemaLogiX team in the preclinical development, translational studies and clinical development programme. She is also responsible for the preclinical and translational studies of HaemaLogix’s LambdaMab™ antibodies, LMCAR™-T cell and bispecific antibody development. Rosanne is an inventor on the company’s patents and was awarded a PhD in antibody engineering from the University of Technology, Sydney. She holds a BSc (Hons), MSc (Medical Science), PhD and is a graduate of the Australian Institute of Company Directors (GAICD).
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.